BioCryst Pharmaceuticals Inc

Financials

Flusso di cassa derivante dalle attività operative -137.22 M-142.16 M-161.85 M-95.14 M-52.02 M347.37 M 347.37 M Flussi di cassa derivanti dalle attività di investimento -6.86 M15.8 M-128.24 M-131.5 M52.59 M-13.69 M -13.69 M Liquidità derivante dalle attività di finanziamento 302.7 M359.67 M88.03 M32.48 M-5.76 M-349.93 M -349.93 M Liquidità libera -137.73 M-144.54 M-163.2 M-97.31 M-53.14 M344.9 M 344.9 M

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.

BCRX

Financials

BioCryst Pharmaceuticals Inc

Notizie

ValuEngine Weekly Market Summary And Commentary

BioCryst nomina Sandeep Menon chief R&D officer

BioCryst 2025: percorso verso 1 miliardo di ricavi, Navenibart amplia il portafoglio

BioCryst Q4 2025: forte crescita, titolo in calo

RBC Capital conferma il rating su BioCryst per potenziale acquisizione

Micron and Intel among market cap stock movers on Monday

X4 Pharmaceuticals: An Undercovered Biotech Trade With A Funded Path To FDA Approval

BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2025 Earnings Call Transcript

TD Cowen conferma rating Buy su BioCryst Pharma per crescita Orladeyo

TD Cowen reiterates BioCryst Pharma stock Buy rating on Orladeyo growth

BioCryst Pharmaceuticals (BCRX) Q4 Earnings and Revenues Surpass Estimates

BioCryst full year 2025 slides: record profit, injectable expansion